The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ranolazine Improves Angina in Women With Evidence of Myocardial Ischemia But No Obstructive Coronary Artery Disease
Open accessAbstract
OBJECTIVES We conducted a pilot study for a large definitive clinical trial evaluating the impact of ranolazine in women with angina, evidence of myocardial ischemia, and no obstructive coronary artery disease (CAD). BACKGROUND Women with angina, evidence of myocardial ischemia, but no obstructive CAD frequently have microvascular coronary dysfunction. The impact of ranolazine in this patient group is unknown. METHODS A pilot randomized, double-blind, placebo-controlled, crossover trial was conducted in 20 women with angina, no obstructive CAD, and ≥10% ischemic myocardium on adenosine stress cardiac magnetic resonance (CMR) imaging. Participants were assigned to ranolazine or placebo for 4 weeks separated by a 2-week washout. The Seattle Angina Questionnaire and CMR were evaluated after each treatment. Invasive coronary flow reserve (CFR) was available in patients who underwent clinically indicated coronary reactivity testing. CMR data analysis included the percentage of ischemic myocardium and quantitative myocardial perfusion reserve index (MPRI). RESULTS The mean age of subjects was 57 ± 11 years. Compared with placebo, patients on ranolazine had significantly higher (better) Seattle Angina Questionnaire scores, including physical functioning (p = 0.046), angina stability (p = 0.008), and quality of life (p = 0.021). There was a trend toward a higher (better) CMR mid-ventricular MPRI (2.4 [2.0 minimum, 2.8 maximum] vs. 2.1 [1.7 minimum, 2.5 maximum], p = 0.074) on ranolazine. Among women with coronary reactivity testing (n = 13), those with CFR ≤3.0 had a significantly improved MPRI on ranolazine versus placebo compared to women with CFR >3.0 (∆ in MPRI 0.48 vs. –0.82, p = 0.04). CONCLUSIONS In women with angina, evidence of ischemia, and no obstructive CAD, this pilot randomized, controlled trial revealed that ranolazine improves angina. Myocardial ischemia may also improve, particularly among women with low CFR. These data document approach feasibility and provide outcome variability estimates for planning a definitive large clinical trial to evaluate the role of ranolazine in women with microvascular coronary dysfunction. (Microvascular Coronary Disease In Women: Impact Of Ranolazine; NCT00570089).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi495 · Cited by 193
Cited by
Coronary microvascular dysfunction: an update
Crea, F., Camici, P. G., & Bairey Merz, C. N. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht513 · Cited by 782
Self-citationBairey Merz, C. N., Pepine, C. J., Walsh, M. N., Fleg, J. L., Camici, P. G., Chilian, W. M., Clayton, J. A., Cooper, L. S., Crea, F., Di Carli, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024534 · Cited by 748
Self-citationKaski, J.-C., Crea, F., Gersh, B. J., & Camici, P. G. (2018) · Circulation · doi:10.1161/circulationaha.118.031373 · Cited by 340
Coronary Microvascular Dysfunction, Microvascular Angina, and Treatment Strategies
Marinescu, M. A., Löffler, A. I., Ouellette, M., Smith, L., Kramer, C. M., & Bourque, J. M. (2015) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2014.12.008 · Cited by 302
Coronary microvascular dysfunction
Sucato, V., Novo, G., Saladino, A., Evola, S., & Galassi, A. R. (2020) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.20.05070-7 · Cited by 30
Metadata
- Authors
- Mehta, P. K., Goykhman, P., Thomson, L. E. J., Shufelt, C., Wei, J., Yang, Y., Gill, E., Minissian, M., Shaw, L. J., Slomka, P. J., Slivka, M., Berman, D. S., & Bairey Merz, C. N.
- Venue
- JACC: Cardiovascular Imaging
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 4
- Issue
- 5
- Pages
- 514-522
- ISSN
- 1876-7591 (ISSN-L)
- 1936-878X
- OpenAlex
- W2042104057
- Cited by
- 224
- References
- 1
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.